Information  X 
Enter a valid email address

Kropz PLC (KRPZ)


Wednesday 08 December, 2021

Kropz PLC

Convertible and Equity Facility Draw Downs

RNS Number : 8959U
Kropz PLC
08 December 2021

8 December 2021

Kropz Plc

("Kropz" or the "Company")


Equity Facility and Convertible Equity Facility Draw Downs


Kropz Plc (AIM: KRPZ), an emerging African phosphate explorer and developer, is pleased to confirm that it has made its fourth draw down request under the US$ 5 million Equity Facility from ARC Fund ("ARC"), the Company's major shareholder (which cannot exceed ZAR 85 million) ("New Equity Facility"), as announced on 26 February 2021 .


The fourth draw down request of US$ 400,000 under the New Equity Facility will be settled by the issue of 6,949,072 new ordinary shares at the issue price of 4.20 pence per share to ARC on 13 December 2021.


The proceeds drawn down from the New Equity Facility will be applied to the continuing workstream on the Hinda project and for general corporate purposes.


The next draw down of US$200,000 under the New Equity Facility is expected to be made on or about 10 March 2021. Following this drawdown, the New Equity Facility will be fully drawn down.


In addition, Kropz announced on 29 September 2021 that it had entered into a new conditional convertible equity facility of up to ZAR 200 million ("New ZAR Equity Facility"), with ARC, in order to deliver the Company's Elandsfontein phosphate project to first revenue. The first drawdown of ZAR90 million of the New ZAR Equity Facility was made on 26 October 2021.

The second drawdown of ZAR37 million of the New ZAR Equity Facility will be made on 10 December 2021. If required, the ZAR73 million remaining on the New ZAR Equity Facility will be drawn down in Q1 2022.


The Company will provide further updates on Elandsfontein and Hinda project progress in late Q4 2021.


Admission and Total Voting Rights


Application will be made for the 6,949,072 new ordinary shares to admission to trading on the AIM Market of the London Stock Exchange ("AIM"). It is expected that admission will become effective and that dealings in the new ordinary shares will commence at 8.00 a.m. on 13 December 2021 ("Admission").


On Admission, the Company's issued share capital will consist of 909,571,975 ordinary shares with voting rights. There are no shares held in treasury. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.


Change in Shareholding


Following issue of the 6,949,072 new ordinary shares, ARC will be directly interested in 760,893,082 ordinary shares of the Company representing 83.65 per cent. of the issued share capital.




For further information visit  or contact:


Kropz Plc


Mark Summers (CEO)

+27 (0) 79 744 8708



Grant Thornton UK LLP

Nominated Adviser

Samantha Harrison

Harrison Clarke

George Grainger


+44 (0) 20 7383 5100



Hannam & Partners


Andrew Chubb

Ernest Bell

 +44 (0) 20 7907 8500




Financial PR & IR (UK)

N ick Elwes

Jos Simson

Oliver Lamb

+44 (0) 207 920 3150

[email protected]



R&A Strategic Communications

PR (South Africa)

James Duncan

+27 (0) 11 880 3924

[email protected] 


About Kropz Plc

Kropz is an emerging African explorer and developer of plant nutrient feed minerals with phosphate projects in South Africa and the Republic of Congo. The vision of the Group is to become a leading independent phosphate rock producer and to develop into an integrated, mine-to-market plant nutrient company focusing on sub-Saharan Africa.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t